

IN THE UNITED STATES DESIGNATED/ELECTED OFFICE

International Application No. : PCT/EP03/05847
International Filing Date : June 4, 2003
Priority Date(s) Claimed : June 4, 2002
Applicant(s) (DO/EO/US) : Florian LANG et al.

Title: SGK AND NEDD USED AS DIAGNOSTIC AND THERAPEUTIC TARGETS

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §§ 1.56, 1.97 and 1.98

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

This information disclosure statement is made in accordance with 37 C.F.R. §§ 1.56, 1.97 and 1.98 as follows:

Timing and Fees

- ☒ Under 37 C.F.R. § 1.97(b), no fee or statement is required for filing this information disclosure statement is filed:
- ☐ within three months of the filing date of a national application other than a CPA under § 1.53(d);
 - ☐ within three months of the actual filing date of the national phase of a PCT application; OR
 - ☒ before the mailing of a first substantive office action (including after filing of an RCE).
- ☐ Under 37 C.F.R. § 1.97(c), this information disclosure statement is filed after the periods specified in 37 C.F.R. § 1.97(b), but before the mailing date of:
- a final rejection under 37 C.F.R. 1.113;
 - termination of prosecution, e.g. Ex Parte Quayle, M.P.E.P § 609(B)(2); OR
 - a notice of allowance under 37 C.F.R. § 1.311; and

is accompanied by:

- ☐ the statement as specified in 37 C.F.R. § 1.97(e) set out below; OR
 - ☐ a check covering the fee of \$180.00 under 37 C.F.R. § 1.17(p).
- ☐ Under 37 C.F.R. § 1.97(d), this information disclosure statement is filed after the mailing date of the following actions which have not been withdrawn:
- ☐ a final action under 37 C.F.R. § 1.113;
 - ☐ termination of prosecution, e.g. Ex Parte Quayle, M.P.E.P § 609(B)(2);
 - ☐ OR a notice of allowance under 37 C.F.R. § 1.311;

AND is filed on or before payment of the issue fee; AND is accompanied by:

the statement as specified in 37 C.F.R. § 1.97(e) as set forth below, and the fee of \$180.00 under 37 C.F.R. § 1.17(p).

Statements Under 37 C.F.R. 1.97(e)

- ☐ Each item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application having a mailing date not more than three months prior to the filing date of this information disclosure statement; or
- ☐ No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and to the knowledge of the undersigned attorney after making reasonable inquiry, no item of information contained in this information disclosure statement was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing date of the information disclosure statement.

Cited Materials

- ☐ Copies of materials listed but not attached were cited in benefit (35 U.S.C. § 120) ancestor application Serial No. _____, on Form 892 by the Examiner and/or Form 1449 by the applicant; see 37 C.F.R. § 1.98(d).
- ☐ Copies of materials listed but not attached were cited in an international search report dated _____.
- ☐ Not required by 37 CFR § 1.98.
- ☒ Copies of the materials listed are attached (except for the foregoing).

Non-English Language References

☐ An English-language search report or equivalent paper from a foreign patent office is provided indicating the relevance of the cited reference(s).

☐ A foreign-language search report from a foreign patent office is provided, and pertinent parts are translated substantively below:

X = document of particular relevance when it is taken alone

Y = document of particular relevance when it is combined with another such document

A = document defining the general state of the art

O = non-written disclosure

P = intercalated document

T = document cited to understand the theory or principle underlying the invention

E = patent document which has the benefit of a date earlier than the filing date and which was published only on or after this filing date

D = cited in the application

L = cited for another reason

& = publication of member of same patent family

☐ Translation of other relevant information on foreign search report

[insert necessary translation here]

Other Information


Payment of Fees Due (If Any):

☐ A check for \$_____ covering the fee identified above is attached.

☐ Please charge to Deposit Account No. 13-3402 \$_____ for the fee identified above.

☒ The Commissioner is hereby authorized to charge or credit any overpayment to Deposit Account #13-3402, two copies of this paper are attached for this purpose.

Respectfully submitted,



Anthony J. Zelano, Reg. No. 27,969
Attorney for Applicants

MILLEN, WHITE, ZELANO
& BRANIGAN, P.C.
Arlington Courthouse Plaza 1
2200 Clarendon Blvd. Suite 1400
Arlington, Virginia 22201
Telephone: (703) 243-6333
Facsimile: (703) 243-6410

Attorney Docket No.: RUFF-3

Date: April 5, 2005

AJZ:aap

K:\RUFF3\Information Disclosure Statement2.doc

Please type a plus sign (+) inside this box.



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 2

Complete if Known

Application Number	10/516,745
Filing Date	December 4, 2004
First Named Inventor	Florian LANG et al.
Group Art Unit	Unknown
Examiner Name	Unknown
Attorney Docket Number	RUFF-3

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	1	"The Merck Index, 13 th Edition" 2001, Merck & Co., INC., WHITEHOUSE STATION, NJ XP002267642.	
	2	"Phosphorylation of Nedd4-2 by Sgk1 regulates epithelial Na ⁺ channel cell surface expression" Christophe Debonneville et al.; The EMBO Journal Vol. 20 No. 24 pp. 7052-7059, 2001.	
	3	"Evidence for an electrogenic, negatively protein-kinase-A-modulated, Na ⁺ -dependent HC0-3 transporter in human lymphocytes" L.A. de la Rose et al.; Pfluegers Arch -Eur J. Physiol (1999) 437:935-943.	
	4	Cellular Physiology and Biochemistry; Cell Physiol Biochem 2000; 10: 187-194 "The Shrinkage-activated Na ⁺ Conductance of Rat Hepatocytes and its Possible Correlation to rENaC" Christoph Boehmer et al.	
	5	"Epithelial sodium channel regulated by aldosterone-induced protein sgk" Sei-Yu CHEN et al.; Proc. Natl. Acad Sci, USA vol. 96, pp. 2514-2519, March 1999.	
	6	"Sgk Is an Aldosterone-induced Kinase in the Renal Collecting Duct" Aniko Naray-Fejes-Toth et al.; The Journal of Biological Chemistry 1999 vol. 274, No. 24, Issue of June 11 pp. 16973-16978, 1999.	
	7	"Deranged transcriptional regulation of cell-volume-sensitive kinase hSGK in diabetic nephropathy" F. Lang et al.; July 5, 2000 vol. 97 no. 14 8157-8162	
	8	"Regulation of sgk by aldosterone and its effects on the epithelial Na ⁺ channel" Alexander Shigaev et al. Am J Physiol Renal Physiol 278: F613-F619, 2000. Department of Biological Chemistry, The Weizmann Institute of Science, Rehovot 76100, Israel	
	9	Cellular Physiology and Biochemistry "Effects of the Serine/Threonine Kinase SGK1 on the Epithelial Na ⁺ -Channel (EnaC) and CFTR: Implications for Cystic Fibrosis" Carsten A. WAGNER et al. ; Cell Physiol Biochem 2001;11-209-218 .	
	10	"Serum-and Glucocorticoid-Regulated Kinase (SGK1) Gene and Blood Pressure" Andreas Busjahn, et al.; 2002 American Heart Association, Inc. pp. 256-260.	
	11	"Immediate-early Transcriptional Regulation and Rapid mRNA Turnover of a Putative Serine/Threonine Protein Kinase" Melanie K. Webster et al; The Journal of Biological Chemistry vol. 268, No. 16. Issue of June 5 pp. 11482-11485, 1993.	
	12	"Characterization of sgk, a Novel Member of the Serine/Threonine Protein Kinase Gene Family Which is Transcriptionally Induced by Glucocorticoids and Serum" Melanie K. Webster et al.; Molecular and Cellular Biology, Apr. 1993, pp. 2031-2040.	
	13	"The Regulation and Physiological Roles of Serum and Glucocorticoid-Induced Protein Kinase" Florian Lang et al.; Published 13 November 2001 pp.1-11.	
	14	"Serum and Glucocorticoid-Inducible Kinase (SGK) is a Target of the P1 3-Kinase-Stimulated signaling Pathway" Jongsun Park et al; The EMBO Journal vol. 18 no. 11 pp. 3024-3033, 1999.	
	15	"Rapid Upregulation of Serum and Glucocorticoid-Regulated Kinase (SGK) Gene Expression by Corticosteroids in Vivo" Francine E. Brennan et al.; Molecular and Cellular Endocrinology 166 (2000) 129-136.	

Please type a plus sign (+) inside this box →



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/516,745
				Filing Date	December 4, 2004
				First Named Inventor	Florian LANG et al.
				Group Art Unit	Unknown
				Examiner Name	Unknown
Sheet	2	of	2	Attorney Docket Number	RUFF-3

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	16	"Expression of serum-and glucocorticoid-regulated kinase (sgk) mRNA is up-regulated by GM-CSF and other proinflammatory mediators in human granulocytes" ; R.T. Cowling et al. Journal of Leukocyte Biology Vol. 67, February 2000.	
	17	"Activation of serum-and glucocorticoid-regulated protein kinase by agonists that activate phosphatidylinositide 3-kinase is mediated by 3-phosphoinositide-dependent protein kinase-1 (PDK1) and PDK2." Takayasu KOBAYASHI et al. Biochem J. (1999) 339-, 319-326	
	18	"Characterization of the structure and regulation of two novel isoforms of serum-and glucocorticoid-induced protein kinase" Takayasu KOBAYASHI et al. Biochem J. (1999) 344., 189-197.	
	19	"Expression cloning and cDNA sequencing of the Na ⁺ /glucose co-transporter" Matthias A. Hediger et al.; Nature vol. 330 26 November 1987.	
	20	Cellular Physiology and Biochemistry 'The use of Xenopus laevis Oocytes for the Functional Characterization of Heterologously Expressed Membrane Proteins" Carsten A. Wagner et al. Cellular Physiol Biochem 2000; 10:1-12.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.